Follow up study of Phase II clinical trial of OCV-501

Follow up study of Phase II clinical trial of OCV-501 - NMC-OCV501-AML

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045499

Enrollment

Registered

2021-09-16

Start date

2021-09-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Registered cases in OCV-501 Phase II study

Exclusion criteria

Exclusion criteria: 1) Cases showing a manifestation of non-participation in this study 2) Cases who the principal investigator deems inappropriate as a research subject

Design outcomes

Primary

Measure	Time frame
5-year disease free survival; OCV-501 group vs. placebo group	—

Secondary

Measure	Time frame
5-year overall survival; OCV-501 group vs. placebo group Specific immunological responses to WT-1 and prognosis Level of WT1 mRNA and prognosis	—

Countries

Japan

Contacts

Public ContactTomoki Naoe

National Hospital Organization Nagoya Medical Center Honorary Director

naoe.tomoki.wx@mail.hosp.go.jp052-951-1111

Outcome results